|
Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents Clinical research trials and Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents. Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents clinical trial. Subjects often receive the most expert healthcare possible for their Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents  Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents
Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents
For Condition: HIV Infections
Status: Terminated
Sponsor(s): National Institute of Child Health and Human Development (NICHD) , National Institute on Drug Abuse (NIDA),National Institute of Mental Health (NIMH),National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Synopsis: This study will attempt to stimulate the immune system in HIV infected adolescents and young adults so that it can better control the HIV infection. When anti-HIV drugs are stopped for a period of time, the virus “grows back.” This may stimulate the immune system, which may then be more effective in controlling the virus.
Details: The focus of this study is to use Structured Treatment Interruption (STI) as an approach to auto-immunization. The STI management schema is based on current understanding of HIV-1 viral dynamics, pharmacology of available antiretroviral medications, and HIV-specific host responses. This is a Phase II trial to provide preliminary data on the feasibility and possible efficacy of using STI to enhance immune-based control of HIV-1 replication. A steady state HIV-1 viral load determined from historical tests prior to initiating highly active antiretroviral therapy (HAART) will be compared to the steady state viral load post-STI. HIV-1 specific CD4 and CD8 cell responses will be measured before and after the period of STI management and HIV-1 specific CD8 cell maturational phenotype will be assessed and correlated with ability to control viral replication. Adolescents and young adults who have either had sustained viral suppression on HAART for at least 2 years or who have had sustained viral suppression from 3 to 6 months will be eligible for this study. Participants will have 12 weeks of HAART followed by 2 to 4 weeks of treatment interruption. Participants will undergo three rounds of this regimen. After the third STI, participants will have an additional 12 weeks of HAART and then stop therapy. Participants will be monitored off HAART for up to 20 weeks. During this time, if there is evidence of HIV progression (two consecutive viral loads exceeding 10,000 copies/ml; two consecutive CD4 cell counts under 350 cells/microL; two consecutive CD4 percentages less than 15%; or two consecutive CD4 cell counts less than 50% of baseline), standard continuous antiretroviral therapy will be reinstituted. Plasma HIV RNA will be tested monthly during therapy and weekly while subjects are off treatment. Immunologic studies are monthly throughout the study. Participants will be involved in the study for approximately 2 years.
Eligibility:
Study Type: Interventional,Treatment,Non-Randomized,Open Label,Uncontrolled,Single Group Assignment,Safety/Efficacy Study
Minimum Age/Maximum Age: 14 Years/21 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Acquired HIV infection after age 12 years - CD4 cell count greater than 500 cells/microL within 30 days of study entry - Either on HAART for 3 to 6 months with HIV-1 RNA < 400 copies/ml or on HAART for more than 2 years with at least one HIV-1 RNA < 400 copies/ml each six month period - HAART regimen of two NRTIs and at least one PI (not nelfinavir) - HIV-1 RNA 5,000 copies/ml prior to HAART and documented CD4 cell values - CMV positive - Ability and willingness of subject (and parent/guardian where required) to give informed consent Exclusion Criteria - Started initial HAART regimen less than one year after known HIV-1 seroconversion - Immunosuppressive therapy - Certain medications - Pregnancy - Evidence of an opportunistic infection - Laboratory values that are classified as Grade 3 or higher toxicities at the time of study enrollment
Total Enrollment: 20
Location and Contact Information:
Overall Study Official:
CraigWilson, Study Chair, University of Alabama, Birmingham
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania,
United States
Children's Diagnostic and Treatment Center
Ft. Lauderdale, Florida,
United States
Children's National Medical Center
Washington D.C., District of Columbia, 20010
United States
University of California at San Diego
San Diego, California,
United States
Additional Information:
Study ID Numbers: ATN 008;
Study Start Date: July 2003
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00067574
Other Hiv Infections Studies:
1. An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)
2. Safety of and Immune System Response to an HIV Vaccine (EP-HIV-1090) in HIV Infected Patients
3. Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium avium Complex Disease (MAC) Plus AIDS
4. Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
5. Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents
|
|
|
|
|
|
|
|
